I'm LongbridgeAI, I can summarize articles.Bioxytran reported a net loss of $2.12 million for the year ended December 31, 2025, with a loss per share of $(0.02). Operating expenses were $1.84 million, leading to a loss from operations of $(1.84 million). The company ended the period with $0.51 million in cash, insufficient to fund operations through July 2026 without additional financing. Management aims to raise $2-3 million in 2026 to sustain operations and initiate pivotal trials, while also advancing clinical candidates and achieving regulatory milestones.
Bioxytran reported a net loss attributable to the company of $2.123077 million for the year ended December 31, 2025, with loss per common share, basic and diluted, of $(0.02) on a weighted average of 91,843,409 shares. Operating expenses totaled $1.842509 million, producing a loss from operations of $(1.842509) million. The company ended the period with $0.510 million in cash and management states existing cash is insufficient to fund operations through July 2026 without additional financing.
Financial Highlights
- Operating expenses: $1.842509 million (Consolidated Statements of Operations)
- Loss from operations (Operating Income): $(1.842509) million
- Net loss (Net Income) attributable to Bioxytran: $(2.123077) million for year ended Dec 31, 2025
- Loss per common share, basic and diluted: $(0.02) (weighted average common shares: 91,843,409)
- Cash, end of period: $0.510 million (improved from $5,154)
Business Highlights
- Clinical development progress: Advanced multiple candidates—BXT-25 reported positive animal toxicity results; ProLectin-M Phase 1b/2a showed faster viral clearance and a Phase 3 is planned for 3Q2026.
- Regulatory milestones: FDA cleared an IND for the PROTECT trial; India’s CDSCO issued INDs for ProLectin-M, ProLectin-I and ProLectin-F, enabling clinical progression in both the U.S. and India.
- R&D focus: Research and development spending increased materially in 2025 to support process, clinical and product development activities tied to advancing clinical candidates.
- Operational runway and funding plan: Management is targeting $2–3 million (noting a need of approximately $3.7 million) in 2026 to sustain operations and initiate pivotal trials, with contingency plans to scale back operations if required financing is not secured.
Original SEC Filing: BIOXYTRAN, INC [ BIXT ] - 10-K - Apr. 15, 2026